PARP1 and ovarian carcinoma: In addition, a recent study has shown that KAT6A knockdown can restore drug sensitivity to poly(ADP‐ribose)‐polymerase (PARP) inhibitor (PARPi) in ovarian cancer cells that develop drug resistance to PARPi [130].